Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Dicloxacillin sodium
Bristol-Myers Squibb Australia Pty Ltd
Medicine Registered
Diclocil Powder for Injection V3.0 PRODUCT INFORMATION DICLOCIL (DICLOXACILLIN SODIUM) POWDER FOR INJECTION NAME OF THE MEDICINE Dicloxacillin sodium is sodium (6R)-6-[3-(2,6-dichlorophenyl)-5-methylisoxazole-4- carboxamido]-penicillanate monohydrate; it is a penicillinase-resistant, acid-resistant, semisynthetic penicillin with the following structure. DESCRIPTION Diclocil powder for injection is a fine white crystalline powder, containing only dicloxacillin 500mg or 1g as sodium dicloxacillin. PHARMACOLOGY _ _ _Pharmacokinetics: _ Dicloxacillin is 95% to 99% bound to serum proteins, mainly albumin. Dicloxacillin is distributed into bone, bile, pleural fluid, and synovial fluid. Only minimal concentrations are attained in cerebrospinal fluid. The elimination half-life of Dicloxacillin is approximately 0.7 hours. Dicloxacillin is partially metabolized to microbiologically active (5-hydroxymethyl derivative of dicloxacillin) and inactive metabolites. Dicloxacillin and its metabolites are rapidly excreted in the urine by glomerular filtration and tubular secretion. The drug is also partially excreted in the faeces via biliary elimination. Reduced plasma concentrations have been reported in patients with cystic fibrosis. This is attributed to enhanced elimination of the drug in these patients. Diclocil Powder for Injection V3.0 2 Dicloxacillin is not dialysable. Only minimal amounts are removed by haemodialysis or peritoneal dialysis. _Pharmacological Actions: _ Penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms d Read the complete document